Torrent Power Q4 FY26 profit falls 69%, dividend ₹20

Key takeaways upfront

Torrent Power reported a sharp year-on-year decline in consolidated net profit for the March 2026 quarter, even as revenue was broadly flat and operating profitability improved marginally. The company also declared a final dividend, taking the total dividend for FY26 to ₹20 per equity share. Separately, Torrent Pharmaceuticals reported steady Q4 FY25 growth on a year-on-year basis, higher full-year FY25 profit, and dividends including an interim payout.

Torrent Power’s March 2026 quarter: headline numbers

For the March 2026 quarter, Torrent Power reported consolidated net profit of ₹318 crore, down 69% year-on-year from ₹1,060 crore in the year-ago quarter. Revenue for the quarter declined marginally to ₹6,406 crore from ₹6,456 crore a year earlier. The profit decline, therefore, came alongside only a small change in topline, highlighting a disconnect between headline earnings and revenue movement.

Operationally, the company reported Ebitda of ₹1,149.3 crore, up 1.7% from ₹1,130.5 crore in the corresponding quarter last year. Ebitda margin improved to 17.9% from 17.5%, indicating slightly better operating efficiency at the consolidated level during the quarter.

Ebit and the generation segment swing

One of the standout disclosures in the quarter was the performance of the generation segment at the Ebit level. Torrent Power’s generation segment reported an Ebit loss of ₹38.9 crore in the March 2026 quarter, compared with an Ebit profit of ₹233.8 crore in the corresponding quarter last year.

This swing in segment Ebit is a material change in operating outcome for that part of the business and sits alongside the company’s overall Ebitda improvement. The data points show that while consolidated operating profitability improved modestly, performance across segments was not uniform in the reported quarter.

Dividend declared: ₹5 final, ₹20 total for FY26

Torrent Power declared a final dividend of ₹5 per equity share for FY26. With an interim dividend of ₹15 per equity share already declared, the total dividend for FY26 stands at ₹20 per equity share.

For income-focused investors, the split between interim and final dividends is an important detail because it indicates the payout cadence across the year. The announcement also provides a clear, quantified shareholder return action even as quarterly profit declined sharply year-on-year.

Torrent Pharmaceuticals Q4 FY25: profit, revenue, and margins

Torrent Pharmaceuticals reported consolidated net profit of ₹498 crore in Q4 FY25. Some filings also cited the year-on-year comparison as ₹498 crore versus ₹449 crore in Q4 FY24, indicating an increase of 10.91% year-on-year.

Revenue from operations for Q4 FY25 was reported at ₹2,959 crore. Additional disclosures cited year-on-year revenue growth of 7.8% to ₹2,959 crore versus ₹2,745 crore in the comparable quarter.

On operating performance, Torrent Pharmaceuticals reported Q4 FY25 Ebitda of ₹964 crore versus ₹883 crore in Q4 FY24, with an operating margin of 32.6% versus 32.2%.

Geographic performance notes: India, Brazil, and US

For Q4 FY25, Torrent Pharmaceuticals’ India business revenue rose 12% to ₹1,545 crore, attributed in disclosures to strong performance in focus therapies. The company also reported that the US market recorded 15% revenue growth in Q4 to ₹302 crore, with constant currency growth at 10%.

Separately stated business commentary cited Q4 FY25 revenue rising 8% year-on-year to ₹2,959 crore, with India business growing 12% and Brazil 5% in constant currency, despite channel de-stocking and currency headwinds.

Full-year FY25: revenue and profit growth

For FY25, Torrent Pharmaceuticals reported net profit of ₹1,911 crore, compared with ₹1,656 crore in FY24. Full-year revenue was reported at ₹11,516 crore, up from ₹10,786 crore year-on-year, with disclosures also describing this as a 7.34% rise in total revenue from operations.

These full-year numbers indicate that the company delivered growth on both profit and revenue for FY25, even as quarter-on-quarter profit movement in Q4 FY25 was described as slightly lower versus Q3 FY25 in one report.

Dividends and key dates at Torrent Pharmaceuticals

Torrent Pharmaceuticals’ board recommended a final dividend of ₹6 per equity share (face value ₹5 each), subject to shareholders’ approval. The record date for the final dividend was set as June 20, with the proposed dividend expected to be paid in August if approved.

The company also paid an interim dividend of ₹26 per equity share during the previous quarter, as per disclosures.

Stock reaction and leadership update

In a market update accompanying the results, Torrent Pharmaceuticals was reported to have risen 1.53% to ₹3,292.95 after the company posted Q4 FY25 net profit of ₹498 crore.

A separate disclosure also noted a leadership change: the board approved the appointment of Aman Mehta as Managing Director, effective 1 August 2025, as part of long-term succession planning.

Summary table of reported metrics

Market impact: what the numbers signal

Torrent Power’s quarter shows that a relatively stable revenue base and slightly improved Ebitda margin did not translate into higher net profit year-on-year. The reported generation segment Ebit swing to a loss is a key operating data point in the quarter’s narrative.

For Torrent Pharmaceuticals, the Q4 FY25 disclosures point to year-on-year growth in revenue, Ebitda, and net profit, along with stable-to-improving margins. The dividend timetable, including the record date and expected payment window (if approved), adds a concrete event track for investors.

Conclusion

Torrent Power’s March 2026-quarter results were marked by a steep year-on-year profit decline, modest Ebitda growth, and a higher margin, alongside a ₹20 per share total dividend for FY26. Torrent Pharmaceuticals, meanwhile, reported Q4 FY25 and full-year FY25 growth, announced a final dividend of ₹6 per share after an interim ₹26 payout, and disclosed its Managing Director appointment effective 1 August 2025.